A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Anthropic’s newly released artificial intelligence (AI) model, Claude Opus 4, is willing to strong-arm the humans who keep it ...

You can catch Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. Nothing lasts forever. And ...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...

Big Pharma is using dark money to fund groups that sound like patient advocacy organizations but represent the industry.

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma ... at a Big Pharma company to advancing novel technology at a young biotech ...

FIRST IN PI — CURRIE HEADS TO BRISTOL MYERS SQUIBB: Bristol Myers Squibb has picked up a veteran drug lobbyist to lead its Washington office at a key moment for the pharmaceutical industry.

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...